Somewhat Negative Media Coverage Somewhat Unlikely to Affect Minerva Neurosciences (NERV) Share Price

Media stories about Minerva Neurosciences (NASDAQ:NERV) have been trending somewhat negative this week, Accern Sentiment reports. The research group identifies negative and positive news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Minerva Neurosciences earned a coverage optimism score of 0.00 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 44.9772160338278 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

A number of brokerages have commented on NERV. ValuEngine cut Minerva Neurosciences from a “sell” rating to a “strong sell” rating in a research report on Friday, April 27th. BidaskClub raised Minerva Neurosciences from a “hold” rating to a “buy” rating in a research report on Saturday, May 26th. Finally, Zacks Investment Research raised Minerva Neurosciences from a “hold” rating to a “buy” rating and set a $7.25 price target for the company in a research report on Friday, March 16th.

NERV traded down $0.05 on Wednesday, reaching $8.40. 3,763 shares of the stock were exchanged, compared to its average volume of 149,170. Minerva Neurosciences has a fifty-two week low of $4.80 and a fifty-two week high of $9.25. The stock has a market cap of $333.24 million, a P/E ratio of -7.78 and a beta of 1.55.

Minerva Neurosciences (NASDAQ:NERV) last issued its quarterly earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($0.32) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($0.04). equities research analysts predict that Minerva Neurosciences will post -1.46 EPS for the current fiscal year.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.

Insider Buying and Selling by Quarter for Minerva Neurosciences (NASDAQ:NERV)

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with's FREE daily email newsletter.

Leave a Reply